Long-term monitoring of mental health in community patients with schizophrenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a cohort of community patients diagnosed with schizophrenia to monitor their mental health throughout their life cycle. It will create a biobank to track disease recurrences, violent behaviors, and other significant outcomes over time. The study will also explore the predictive effects of various biological, psychosocial, and imaging indicators on patient outcomes. By focusing on long-term follow-up, this research seeks to fill the gap in existing studies that primarily rely on cross-sectional data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Registered in the Shanghai Mental Health Information Management System.
* Meets criteria for the diagnosis of schizophrenia (ICD-10 or ICD-11).
* Patients with schizophrenia diagnosed within five years.
* Aged between 18 and 65 years.

Exclusion Criteria:

* Patients with severe physical diseases and organic brain diseases.
* The patient is about to settle outside Shanghai.

Where it's running

• Shanghai Mental Health Center
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Weibo Zhang
• Email: zhangweibo600@163.com
• Phone: 86-18918516651

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• XEP527 in stable schizophrenia: safety and how it behaves in the body

  This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.

  Recruiting Phase 1 Novartis · Bentonville, Arkansas · NCT07908680

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

• Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder

  This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.

  Recruiting Bosnalijek D.D · Sarajevo · NCT07858565

• Neuronavigated rTMS for treatment-resistant auditory hallucinations

  We are testing whether personalized neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations in adults who don’t respond to medication.

  Recruiting Psychiatric University Hospital, Zurich · Zurich · NCT07856368

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.